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Long-term glycemic control and kidney function in insulin-dependent
diabetes mellitus. In this paper we examined the relationship between
blood glucose control and initiation and progression of increased
urinary albumin excretion. In this seven year Oslo study 45 insulin-
dependent diabetes mellitus patients were initially randomized into
three different modes of treatment: continuous subcutaneous insulin
infusion (CSII), multiple injections, or two injections a day. After four
years, the patients were free to choose their treatment, and therefore
the data were analyzed according to mean HbAI during seven years.
The mean HbAI was 11.2% (2,2) (SD) at start, and 9.5% (1.5) at seven
years, which was a significant long-term improvement (P < 0.001).
Eight out of 10 patients with mean seven year HbAI < 8.5% improved
their albumin excretion rate, and patients with mean HbA1 > 10% had
an increased albumin excretion rate (from 26 mg/24 hr to 91 mg124 hr, P
< 0.02). The giomerular filtration rate decreased slightly regardless of
mean HbA1 level. Systolic blood pressure increased significantly
regardless of mean HbAI. Diastolic blood pressure was unchanged in
the patients with mean HbAl less than 10%, but increased slightly (NS)
in patients with HbA1 > 10%. We conclude that mean blood glucose as
measured by glycosylated hemoglobin is a main determinant in the
progression of urinary albumin excretion in insulin dependent diabetics,
and near normoglycemia improves urinary albumin excretion.
Methods
Subjects
In 1982 forty-five patients gave written informed consent to
participate in the study. The protocol was approved by the
Ethical Committee of the Norwegian Council for Science and
the Humanities.
The patients fulfilled the following criteria: age between 18
and 45 years, diagnosis of diabetes before 30 years of age,
duration of disease more than 7 but less than 30 years, no
clinical signs of nephropathy (serum creatinine < 150 mol/
liter) or systematic hypertension (diastolic blood pressure <100
mm Hg), no history of neuropathy, no proliferative retinopathy,
not pregnant, negative for C-peptide (<0.1 nmol/liter 6 mm after
administration of 1 mg glucagon i.v.), and using no medication
other than insulin (except contraceptives). None of the patients
used antihypertensive treatment. Two patients were discovered
to have intermittent proteinuria in the pre-period and were
excluded from the statistical analysis. One patient did not meet
for follow-up examinations in 1989.
Design and treatment
Nephropathy is the major life-threatening complication of
insulin-dependent diabetes mellitus (IDDM), developing in ap-
proximately 30% of patients [11. The first serious sign of
diabetic kidney disease is persistently elevated urinary albumin
excretion as detected by sensitive assays (microalbuminuria 30
to 300 mg/24 hr) [2—4]. Several cross sectional and long-term
retrospective studies show that patients with microalbuminuria
have higher mean blood glucose and glycosylated hemoglobin
levels than matched normoalbuminuric controls [5—101. This
indicates that diabetic nephropathy may be prevented by strict
glycemic control, and this has been addressed by several
intervention studies [11—13]. We reported a reduction of urinary
albumin excretion during four years of near-normoglycemia
obtained by insulin pump treatment [14]. In this paper we report
the results on the same patients followed prospectively since
1982, demonstrating the beneficial effect of strict blood glucose
control on the progression of early diabetic nephropathy.
During a two month pre-period, home blood glucose moni-
toring was introduced and baseline results obtained. All pa-
tients used two daily insulin injections. They were then ran-
domly assigned to three different modes of treatment:
continuous subcutaneous insulin infusion (CSII) with portable
pumps, multiple injections by means of insulin pens (Novo
Nordisk, Denmark), or continued conventional treatment with
two daily injections of individually mixed rapid-NPH insulins.
In the multiple injection group rapid acting insulin was injected
before each meal (4 to 6 >< daily) and NPH insulin given at
bedtime. CSII and multiple injections were started and opti-
mized during a five day stay in the Diabetes Unit in the Medical
Department. The patients were followed by the same two
investigators in the out-patient clinic every one to four months
thereafter. After the four year reports [15] the patients could
freely choose the mode of treatment. Today 10 patients use
CSII, two patients use two daily injections and 33 use multiple
injections. The latter is now the generally most preferred
treatment of insulin-dependent diabetes in Norway (>60%).
Methods
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Glycemic control was monitored by measuring stable glyco-
sylated hemoglobin (HbAI, reference values 5.4 to 7.6%,
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Table I.
differe
Urinary albumin excretion rate and GFR, mean (SD), at
nt levels of blood glucose control during seven years
Urinary albumin GFR
mg/24 hr mI/mm 1.73 m2
Start 7 years Duff. Start 7 years Duff.
interassay coefficient of variation <5%) at each visit. Mean of
all measurements after randomization was used for statistical
analysis. The patients performed home blood glucose monitor-
ing by means of Haemoglucotest 1-44 regularly. After the
second year these results were not systematically reported.
Each patient made 6 to 30 (mean 18) 24-hour urine collections
during the study, which totaled 756 samples. Vigorous exercise
was avoided on the days of collections. All urine produced
during the 24 hours preceding a visit to the out-patient clinic
was collected and the volume measured. A 10 ml specimen was
stored at —20°C until analysis. Urine albumin was determined
by an immunonephelometric assay (CV <7%) [14]. To minimize
the effect of the individual day-to-day variations of urinary
albumin excretion, mean values were calculated in each patient.
Glomerular filtration rate (5 'EDTA clearance) was measured
in 1982 and 1989 in all patients by the same investigator (T.B.)
by the method of BrØchner-Mortensen, and related to body
surface (normal range 79 to 131 mI/mm X 1.73 m2). Blood
pressure was measured after 20 minute supine rest and diastolic
pressure was recorded when the Korotkoffs sounds disap-
peared (Phase 5).
Results
Participation in the study significantly reduced the mean
HbA 1 level of the patients through seven years compared to the
level at inclusion. The mean HbA 1 was 11.2 (2.2)% (SD)at start,
and 9.5 (1.5)% was the mean over the next seven years (range
7.5 to 13.2%), which proved to be a significant long-term
improvement (P < 0.001). After four years of strict randomiza-
tion, the looser allocation of treatment, according to the pref-
erence of the patients, did not show any upward drift in HbAl
with time. The mean four and seven year HbA1, according to
the original randomization ("intention to treat") were: insulin
pump group (N = 15) 9.1% and 9.1%, multiple injection group
(N 15) 9.3% and 9.3%, and conventional treatment group (N
= 15) 10.4% and 10.5%, respectively.
Strict glycemic control retarded the progression of nephrop-
athy at this very early stage. When patients were grouped
according to mean seven year's HbAl, in those with HbAl <
9% (N = 17), HbA1 9.1 to 10% (N = 11), and HbAl > 10% (N
14), only the latter group showed a significant deterioration in
urinary albumin excretion rate (Table 1). In the group HbA 1 >
10%, 4 of 14 patients increased more than 200 mg124 hr, versus
none in the other groups (P = 0.02). Half of the patients (N =
4) with HbAI > 10.5% increased more than 200 mg/24 hr, and
8 out of 10 patients with HbA1 < 8.5% improved urinary
Fig. 1. Change in urinary albumin excretion rate during seven years
related to mean HbA1 in the individual patients.
albumin excretion during seven years (Fig. 1). When observing
the groups according to "intention to treat" the conventional
treatment group increased urinary albumin excretion from
mean 21 to 67 mg/24 hr, while the multiple injection and insulin
pump groups increased from 17 to 33 mg/24 hr and 26 to 41
mg/24 hr, respectively (NS).
GFR did not change significantly when grouped according to
HbA1, although a slight reduction within the normal range was
observed in all groups (Table I). Systolic blood pressure
increased from 125 (range 110 to 160) to 131 (range 105 to 165)
mm Hg in the total material (P < 0.01); however, no group
differences were observed. Diastolic blood pressure remained
stable in the total material, 81(70 to 95) and 81(60 to 100) mm
Hg. A modest, insignificant increase (3 mm) was observed in
the group with HbA1 > 10%.
Discussion
This study shows that only insulin dependent diabetics with
glycosylated hemoglobin levels more than 10% progressed
more than 200 mg/24 hr in urinary albumin excretion during
seven years. This study was an intervention study, and the
HbA1  9% 20(11) 25 (23) 5 (23) 115 (12) 108 (15) —7 (14)
N = 17
HbA1 9.1—10% 17(9) 25 (13) 8 (13) 114 (14) 107 (12) —6(8)
N= 11
HbA1 > 10% 26(22) 91 (1l5)° 65 (107) 118 (15) 114 (14) —4(14)
N = 14
a P = 0.02 compared to start
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diabetics had a mean improvement in glycosylated hemoglobin
of 1.7% during seven years. Although the randomization pro-
cedure was suspended after four years, the intention to treat
analysis showed a trend that those initially allocated to two
injections a day had a larger increment in urinary albumin
excretion (mean 46 mg124 hr) than the other two treatment
groups (15 and 16 mg/24 hr). Furthermore, 8 out of 10 patients
with mean HbA1 < 8.5% improved urinary albumin excretion
during the seven years. In the present study, glomerular filtra-
tion rate did not change significantly during the follow-up
period. However, during the initial phase (the first 6 months) a
significant drop in GFR was reported in the CSII treated
patients due to reduction of mean blood glucose level [14].
Thereafter GFR was stable in all treatment groups and no
difference in GFR according to HbA1 levels was noticed. No
significant difference in the progression of arterial hypertension
was noted when comparing groups with different mean HbA1.
Generally the progression rate of kidney disease was rather
slow in the present study. It is necessary to realize that in
contrast to many other studies many of the patients in the
present study did not have established microalbuminuria at
inclusion, They were included because they had more than
seven years duration and the present study is thus an earlier
study than former studies in the field.
The Steno II study randomized diabetics with established
microalbuminuria to either CS!! or conventional treatment [11].
Five patients in the conventionally treated group developed
clinical nephropathy (UaIb > 300 mg/24 hr) and none in the
insulin pump treated group. A follow-up study [161 combined
this study with Steno I [12]. The follow-up period was eight
years (Steno I) and five years (Steno I!). The patients were
analyzed according to their original treatment groups, although
some had changed treatment after two years. A combined
analysis of the 5! patients with microalbuminuria at entry
demonstrated no significant progression of disease among 32
patients with an initial albumin excretion between 30 to 99
mg/24 hr. Among the 19 patients with an initial albumin excre-
tion between 100 and 300 mg/24 hr, however, a significant
treatment effect was demonstrated. Clinical nephropathy (10/10
vs. 2/9, P < 0.01) and arterial hypertension (7/10 vs. 1/9, P <
0.01) was diagnosed more often in the conventionally treated
group than in the insulin infusion group, and glomerular filtra-
tion rate declined significantly during conventional treatment
but not in the insulin infusion group.
The Stockholm study randomized 96 IDDM patients to
intensified conventional treatment or insulin once or twice
daily, and followed them for five years. HbAlc fell from 9.5 to
7.2% in the intensely treated group and from 9.4 to 8.7% (NS)
in the regular treatment group [13]. Eight patients in the regular
treatment group developed diabetic nephropathy, but none in
the intensely treated group. The changes in urinary albumin
excretion during five years were analyzed with logistic regres-
sion and found to relate to mean HbAlc in a dose dependent
matter and not to treatment modality. A significant reduction in
GFR was shown in both groups.
It adds to the strength of our data that we found in the same
study that mean HbA1 of more than 10% during seven years
also confers susceptibility to progression of retinopathy [17],
and a large decline in both sensory and motor nerve conduction
velocity (unpublished data), in contrast to those with HbA1 less
than 9%.
We conclude that substantial progression of urinary albumin
excretion (>200 mg/24 hr) is found only in the patients with
HbA1 (HbA1 >10%) during seven years. Interestingly, those
diabetics with near normoglycemia (HbA1 <8.5%) diminished
their urinary albumin excretion during seven years, suggesting
that microalbuminuria may no longer predict transition to
macroalbuminuria in well-regulated insulin-dependent diabet-
ics. Thus, the mean blood glucose level is a major determinant
of progression of early diabetic kidney disease.
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